ArchiveApril 2016

EMA Panel Backs Daclizumab (Zinbryta) for Multiple Sclerosis

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for daclizumab (Zinbryta, Biogen Idec) for the treatment of adults with relapsing forms of multiple sclerosis (RMS). Daclizumab is given by self-administered subcutaneous injection once a month. The humanized monoclonal antibody selectively binds to the...

What Does DrK think….Practice what you Preach!

Yesterday’s drug delivery, giving six people options where there maybe none…and saving the NHS up to £600,000.                   Can’t wait for the EMA…Cladribine Ready to Go  For those Health Care professionals and People with MS who may be interested.  We have updated our Information concerning off-label...

Competition for Canbex

As you may know we are trying to develop a treatment for spasticity. Baclofen is the usual go to drug, but it is not without its problems. One is the Zombie effect because it is very sedating because it is sedative, because it inhibits nerve function making muscle weakness and having cognitive effects.  It also has a low binding affinity for its target the GABA B receptor. So you need high...

Alemtuzumab 10 years on

P2.086 – Incidence and Timing of Thyroid Adverse Events in Patients with RRMS Treated with Alemtuzumab through 5 Years of the CARE-MS Studies P.A senior et al. OBJECTIVE: To summarize 5-year incidence and timing of thyroid adverse events following alemtuzumab treatment in the ongoing CARE-MS extension study. BACKGROUND: In the phase 3 CARE-MS studies, patients with active relapsing...

The resources debacle

Lancet. 2016 Apr 5. pii: S0140-6736(16)00620-6. doi: 10.1016/S0140-6736(16)00620-6. [Epub ahead of print] Clinical workload in UK primary care: a retrospective analysis of 100 million consultations in England, 2007-14. Hobbs FD, Bankhead C, Mukhtar T, Stevens S, Perera-Salazar R, Holt T, Salisbury C; National Institute for Health Research School for Primary CareResearch. Abstract BACKGROUND:...

Remyelination to Neuroprotection at the AAN

Neuroprotective and oligodendrocyte precursor cell differentiation promoting activities of the RXR nuclear receptor agonist IRX4204 are potentiated by thyroid hormone  Authors: Martin Sanders, MD; Robin Avila, PhD; Bruce Trapp, PhD; Satish Medicetty, PhD; Rosh Chandraratna, PhD  Objective: (1) determine if the RXR nuclear receptor agonist IRX4204 is effective in an in vivo...

When Trials Go Wrong

This is taken from Neurosens and reports on the disasterous trial that led to one person death aand others brain damaged. It has nothing whatso ever to do with MS but some of you may be interested. It is about the drug trial that went wrong. Serious toxicities occurred with the experimental drug BIA 10‐2474, “as if something gave way or swung suddenly at a specific dose or concentration...

ASCEND TRIAL AT AAN

Natalizumab versus placebo in patients with secondary progressive multiple sclerosis (SPMS): results from ASCEND, a multicenter, double-blind, placebo-controlled, randomized phase 3 clinical trial Authors: Deborah Steiner; Douglas Arnold, MD; Mark Freedman, MD, FAAN; Myla Goldman, MD; Hans-Peter Hartung, MD, FAAN; Eva Havrdova, MD; Douglas Jeffery, MD, PhD; Raj Kapoor; Aaron Miller, MD, FAAN;...

NEDA on natalizumab

Prosperini L, Fanelli F, Pozzilli C. Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis. J Neurol Sci. 2016;364:145-7. In this study we assessed the proportion of patients with relapsing multiple sclerosis (R-MS) who had No Evidence of Disease Activity (NEDA-3), defined as absence of relapses, absence of confirmed disability worsening, and...

Translate

Categories

Recent Posts

Recent Comments

Archives